Trial Profile
Open-labled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin
- Indications Malignant pleural effusion; Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Jun 2013 Primary endpoint 'Objective-clinical-response-rate' has been met.
- 01 Jun 2013 Status changed from recruiting to completed.
- 20 Aug 2012 New trial record